MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $13.13 Million Position in Zoetis Inc. $ZTS

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. has reduced its stake in Zoetis Inc. by 6.4%, selling 5,473 shares in the first quarter, resulting in a total holding of $13.1 million worth of shares.
• Several hedge funds have made significant moves with Zoetis stock, including Nuveen LLC purchasing a new position worth approximately $616 million during the same period.
• Zoetis' recent earnings report showed an EPS of $1.76, exceeding analyst estimates, with a revenue of $2.46 billion, reflecting a year-over-year growth of 4.2%.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. decreased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 6.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 79,762 shares of the company's stock after selling 5,473 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Zoetis were worth $13,133,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. 1248 Management LLC bought a new position in shares of Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in shares of Zoetis in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC boosted its holdings in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after acquiring an additional 164 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Down 1.5%

Shares of Zoetis stock traded down $2.28 during midday trading on Friday, reaching $148.33. 3,111,229 shares of the company's stock traded hands, compared to its average volume of 2,249,190. The company has a market cap of $65.74 billion, a price-to-earnings ratio of 25.53, a price-to-earnings-growth ratio of 2.38 and a beta of 0.88. The company's 50 day simple moving average is $152.32 and its 200 day simple moving average is $157.21. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on ZTS shares. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Argus reissued a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Zoetis has a consensus rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.